Drug Trial Radar · NCT07428473
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Monash UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Scribe Therapeutics Inc.
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.
Conditions
- Elevated LDL-C and High Cholesterol
Interventions
STX-1150Drug
Drug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 52 from administration of STX-1150
- Incidence and Severity of Serious Adverse Events (SAEs)Time frame: Up to Week 52 from administration of STX-1150
- Incidence and Severity of Adverse Events of Special Interest (AESI)Time frame: Up to Week 52 from administration of STX-1150
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Monash Health/ Victorian Heart Hospital (VHH)
Clayton, Victoria, Australia · Recruiting
Aotearoa Clinical Trials/Middlemore Hospital
Papatoetoe, Auckland, New Zealand · Recruiting
New Zealand Clinical Research (NZCR)
Christchurch, Christchurch, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.